Robeco Institutional Asset Management B.V. Sells 66,848 Shares of Merck & Co., Inc. (MRK)
Robeco Institutional Asset Management B.V. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 2.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 2,313,056 shares of the company’s stock after selling 66,848 shares during the quarter. Merck & Co., Inc. comprises about 0.7% of Robeco Institutional Asset Management B.V.’s holdings, making the stock its 26th biggest position. Robeco Institutional Asset Management B.V.’s holdings in Merck & Co., Inc. were worth $140,417,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the stock. Clearwater Capital Advisors LLC acquired a new position in Merck & Co., Inc. during the first quarter worth $103,000. SRS Capital Advisors Inc. grew its position in shares of Merck & Co., Inc. by 208.4% in the first quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock valued at $108,000 after purchasing an additional 1,340 shares during the last quarter. Taylor Wealth Management Partners acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $110,000. Creative Financial Designs Inc. ADV grew its position in shares of Merck & Co., Inc. by 155.2% in the second quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock valued at $111,000 after purchasing an additional 1,114 shares during the last quarter. Finally, Well Done LLC acquired a new stake in shares of Merck & Co., Inc. in the first quarter valued at about $115,000. Institutional investors and hedge funds own 72.19% of the company’s stock.
In related news, insider Sanat Chattopadhyay sold 29,208 shares of Merck & Co., Inc. stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $65.20, for a total transaction of $1,904,361.60. Following the sale, the insider now directly owns 70,675 shares of the company’s stock, valued at $4,608,010. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Rita A. Karachun sold 5,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $65.01, for a total value of $325,050.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 396,393 shares of company stock worth $25,235,061. 0.32% of the stock is owned by company insiders.
MRK stock opened at $69.86 on Thursday. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $70.59. The stock has a market cap of $186.25 billion, a P/E ratio of 16.45, a PEG ratio of 2.38 and a beta of 0.81. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.33.
Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.03. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The business had revenue of $10.47 billion for the quarter, compared to the consensus estimate of $10.28 billion. During the same period last year, the business earned $1.01 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. sell-side analysts predict that Merck & Co., Inc. will post 4.27 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 5th. Investors of record on Monday, September 17th will be given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date is Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.24%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Recommended Story: Should you buy a closed-end mutual fund?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.